These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15072549)

  • 21. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
    Hu X; Feng Y; Liu X; Zhao XF; Yu JH; Yang YS; Sydow-Bäckman M; Hörling J; Zierath JR; Leng Y
    Diabetologia; 2007 May; 50(5):1048-57. PubMed ID: 17333104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
    Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
    Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
    Mourad AAE; Mourad MAE
    Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
    Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.
    Kim KY; Cho HS; Jung WH; Kim SS; Cheon HG
    Mol Pharmacol; 2007 Jun; 71(6):1554-62. PubMed ID: 17337625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
    Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
    J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes.
    Lee TC; Miller WL; Auchus RJ
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2104-10. PubMed ID: 10372718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
    Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
    J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice.
    Johnston TP; Waxman DJ
    Can J Physiol Pharmacol; 2008 Sep; 86(9):643-9. PubMed ID: 18758514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
    Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
    Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
    Berthiaume M; Sell H; Lalonde J; Gélinas Y; Tchernof A; Richard D; Deshaies Y
    Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
    Christensen KB; Minet A; Svenstrup H; Grevsen K; Zhang H; Schrader E; Rimbach G; Wein S; Wolffram S; Kristiansen K; Christensen LP
    Phytother Res; 2009 Sep; 23(9):1316-25. PubMed ID: 19172665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
    Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
    Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.